CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.

View All HCPCS Sections

• Q5133

  Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg

• Q5134

  Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg

• Q5135

  Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg

• Q5136

  Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg

• Q5137

  Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg

• Q5138

  Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg

• Q5139

  Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg

• Q5140

  Injection, adalimumab-fkjp, biosimilar, 1 mg

• Q5141

  Injection, adalimumab-aaty, biosimilar, 1 mg

• Q5142

  Injection, adalimumab-ryvk biosimilar, 1 mg

• Q5143

  Injection, adalimumab-adbm, biosimilar, 1 mg

• Q5144

  Injection, adalimumab-aacf (idacio), biosimilar, 1 mg

• Q5145

  Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg

• Q5146

  Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg

• Q5147

  Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg

• Q5148

  Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram

• Q5149

  Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg

• Q5150

  Injection, aflibercept-mrbb (ahzantive), biosimilar, 1 mg

• Q5151

  Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg

• Q5152

  Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg

• Q5153

  Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg

• Q5154

  Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg

• Q5155

  Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg

• Q5156

  Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg

• Q5157

  Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg

• Q5158

  Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg

• Q5159

  Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg

• Q5160

  Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg

• Q5161

  Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg

• Q5162

  Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg

• Q5164

  Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg

• Q5165

  Injection, denosumab-mobz (oziltus), biosimilar, 1 mg

• Q5166

  Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg

• Q5167

  Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg

• Q5168

  Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg

• Q5169

  Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg

• Q5170

  Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg

• Q5171

  Injection, denosumab-mobz (boncresa), biosimilar, 1 mg

• Q9001

  Assessment by chaplain services

• Q9002

  Counseling, individual, by chaplain services

• Q9003

  Counseling, group, by chaplain services

• Q9004

  Department of veterans affairs whole health partner services

• Q9950

  Injection, sulfur hexafluoride lipid microspheres, per ml

• Q9951

  Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml

• Q9953

  Injection, iron-based magnetic resonance contrast agent, per ml

• Q9954

  Oral magnetic resonance contrast agent, per 100 ml

• Q9955

  Injection, perflexane lipid microspheres, per ml

• Q9956

  Injection, octafluoropropane microspheres, per ml

• Q9957

  Injection, perflutren lipid microspheres, per ml

• Q9958

  High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 7/21/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.